| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0015-0282(00)01666-6 |
| P698 | PubMed publication ID | 11163815 |
| P2093 | author name string | Wang P | |
| Cameron D | |||
| Glueck CJ | |||
| Phillips H | |||
| Sieve-Smith L | |||
| P2860 | cites work | Thrombophilia-associated pregnancy wastage | Q33773160 |
| The importance of diagnosing the polycystic ovary syndrome | Q33945491 | ||
| Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy | Q34340770 | ||
| Antepartum testing | Q40842664 | ||
| Metformin in management of pregnant insulin-independent diabetics | Q41493866 | ||
| The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications | Q47866791 | ||
| Increased frequency of genetic thrombophilia in women with complications of pregnancy | Q47868847 | ||
| Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. | Q50895589 | ||
| Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). | Q51557069 | ||
| Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. | Q51559345 | ||
| Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients. | Q51559659 | ||
| Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. | Q51564055 | ||
| Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. | Q51576091 | ||
| Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. | Q51578585 | ||
| The management of non-insulin-dependent diabetes during pregnancy | Q69985653 | ||
| The plasminogen activator system in women with polycystic ovary syndrome | Q74296167 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | abortion | Q8452 |
| human pregnancy | Q11995 | ||
| miscarriage | Q28693 | ||
| polycystic ovary syndrome | Q500816 | ||
| polycystic ovary | Q5547896 | ||
| metformin | Q19484 | ||
| P304 | page(s) | 46-52 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Fertility and Sterility | Q15724525 |
| P1476 | title | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study | |
| P478 | volume | 75 |
| Q36268407 | 4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome |
| Q44135617 | A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage |
| Q37825558 | Acne-associated syndromes: models for better understanding of acne pathogenesis |
| Q45918351 | Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. |
| Q35776464 | Assisted reproduction in the treatment of polycystic ovarian syndrome |
| Q33901117 | Association of polycystic ovary syndrome and a non-dipping blood pressure pattern in young women |
| Q45917076 | Association of polycystic ovary syndrome with cardiovascular risk factors. |
| Q39133343 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. |
| Q24642229 | Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective, case-control study |
| Q36789507 | Comparison of newborn outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a randomised blinded trial |
| Q36935506 | Contemporary Reproductive Outcomes for Patients With Polycystic Ovary Syndrome: A Retrospective Observational Study. |
| Q46608748 | Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity |
| Q33844752 | Controversies around gestational diabetes. Practical information for family doctors. |
| Q73897306 | Current awareness in prenatal diagnosis |
| Q34203216 | Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome |
| Q34490723 | Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet |
| Q62538125 | Effect of Type 2 Diabetes Mellitus on the Pharmacokinetics of Metformin in Obese Pregnant Women |
| Q22242102 | Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial |
| Q33717826 | Effect of green tea on metabolic and hormonal aspect of polycystic ovarian syndrome in overweight and obese women suffering from polycystic ovarian syndrome: A clinical trial |
| Q26991523 | Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis |
| Q45993193 | Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Q42165613 | Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome |
| Q38600177 | Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis |
| Q46187383 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss |
| Q34658641 | Epidemiology, diagnosis, and management of polycystic ovary syndrome |
| Q37547069 | Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. |
| Q34196682 | Evaluation of the effect of metformin and aspirin on utero placental circulation of pregnant women with PCOS |
| Q24629523 | Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence |
| Q34421386 | First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis |
| Q36398652 | Gestational diabetes: after the ACHOIS trial |
| Q36868187 | How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation |
| Q37280333 | Idiopathic hirsutism and insulin resistance. |
| Q44524406 | Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome |
| Q44127878 | Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss |
| Q44420202 | Insulin resistance and polycystic ovary syndrome |
| Q37833622 | Insulin resistance and the long-term consequences of polycystic ovary syndrome |
| Q35564923 | Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome |
| Q36664808 | Insulins and oral hypoglycemic agents in pregnancy |
| Q36673559 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? |
| Q36001614 | Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome? |
| Q51808023 | Is there a need for recombinant human luteinizing hormone (lutropin alfa) supplementation in ovarian stimulation for assisted reproduction? |
| Q35196438 | Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? |
| Q35489121 | Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss |
| Q42868207 | Metformin Versus Placebo from First Trimester to Delivery in Polycystic Ovary Syndrome: A Randomized, Controlled Multicenter Study |
| Q35179344 | Metformin and gestational diabetes |
| Q34746925 | Metformin and polycystic ovary syndrome |
| Q36762451 | Metformin before and during pregnancy and lactation in polycystic ovary syndrome |
| Q39583558 | Metformin exposure affects human and mouse fetal testicular cells. |
| Q36283811 | Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents |
| Q34451719 | Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects |
| Q42518054 | Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome |
| Q46955555 | Metformin use and diabetic pregnancy-has its time come? |
| Q34683828 | Metformin use during the first trimester of pregnancy. Is it safe? |
| Q34357971 | Metformin use in women with polycystic ovary syndrome |
| Q44990825 | Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome |
| Q22241434 | Metformin: new understandings, new uses |
| Q43878359 | Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy |
| Q37079215 | Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis |
| Q26851879 | Oral Hypoglycemic Agents in pregnancy: An Update |
| Q84311034 | Oral agents in the management of the pregnancy complicated by gestational diabetes mellitus: increased options |
| Q34975778 | Oral antihyperglycemic agents during pregnancy and lactation: a review |
| Q37826425 | Oral hypoglycemic agents for gestational diabetes mellitus? |
| Q36477861 | Outcome of clinical pregnancies after ovulation induction using metformin |
| Q44517697 | Ovulation induction--optimizing results and minimizing risks |
| Q77399415 | Pharmacoepidemiology and drug safety |
| Q46148241 | Plasminogen activator inhibitor 1 4G/5G and -844G/A variants in idiopathic recurrent pregnancy loss |
| Q33723471 | Polycystic ovarian syndrome: diagnosis and management |
| Q36935621 | Polycystic ovary syndrome and maternal obesity affect oocyte size in in vitro fertilization/intracytoplasmic sperm injection cycles |
| Q36622133 | Polycystic ovary syndrome in adolescents: current and future treatment options |
| Q43950313 | Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome |
| Q36862243 | Pregnancy in polycystic ovary syndrome |
| Q36402610 | Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? |
| Q45117379 | Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin |
| Q44198605 | Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin |
| Q34257603 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview |
| Q33713930 | Recurrent pregnancy loss: current perspectives |
| Q38653942 | Recurrent triploid digynic conceptions and mature ovarian teratomas: Are they different manifestations of the same genetic defect? |
| Q83154838 | Response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia |
| Q35996544 | Revisit of metformin treatment in polycystic ovarian syndrome |
| Q44456248 | Should infertile women with polycystic ovarian syndrome be treated with metformine? |
| Q34512903 | Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome |
| Q34190360 | The comparison of insulin resistance frequency in patients with recurrent early pregnancy loss to normal individuals |
| Q35000949 | The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin |
| Q38027183 | The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis |
| Q43810907 | The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials |
| Q43267068 | The evaluation and treatment of hirsute women |
| Q35196447 | The importance of insulin resistance in polycystic ovary syndrome |
| Q43815049 | The ovary and insulin resistance |
| Q35608887 | The pathophysiology of polycystic ovary syndrome |
| Q34994296 | The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. |
| Q35606054 | Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS). |
| Q35649437 | Treatment of PCOS with metformin and other insulin-sensitizing agents |
| Q44648893 | Use of clomiphene citrate in women |
| Q34495778 | Use of metformin in polycystic ovary syndrome |
| Q37769526 | Use of metformin in the treatment of polycystic ovary syndrome |
| Q36799638 | Using evidence from randomized trials in fertility practice |
Search more.